Literature DB >> 9223470

The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein.

K Juhasz1, S S Whitehead, P T Bui, J M Biggs, J E Crowe, C A Boulanger, P L Collins, B R Murphy.   

Abstract

cpts530, a candidate live-virus vaccine, is an attenuated strain of human respiratory syncytial virus (RSV). It was derived by subjecting a cold-passaged (cp) strain of RSV to a single round of chemical mutagenesis. cpts530 is a temperature-sensitive (ts) mutant that is attenuated in mice and chimpanzees, and its ts phenotype exhibits a high level of stability during replication in both species. In the present study, the complete nucleotide sequence of cpts530 RSV was determined. The five mutations known to be present in the parent cpRSV were retained in its cpts530 derivative, and one additional nucleotide change was identified at nucleotide (nt) 10060, which resulted in a phenylalanine-to-leucine change at amino acid 521 in the large polymerase (L) protein. To determine if this single amino acid substitution was indeed responsible for the ts phenotype of cpts530, it was introduced alone or in combination with the cp mutations into the full-length cDNA clone of the wild-type A2 RSV. Analysis of infectious viruses recovered from mutant cDNAs indicated that this single mutation specified complete restriction of plaque formation of recombinant cp530 in HEp-2 cell monolayer cultures at 40 degrees C, and the level of temperature sensitivity was not influenced by the presence of the five cpRSV mutations. These findings identify the phenylalanine-to-leucine change at amino acid 521 in the L protein as the mutation that specifies the ts phenotype of cpts530. Furthermore, these findings illustrate the feasibility of using the cDNA-based recovery system to analyze and construct defined attenuated vaccine viruses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223470      PMCID: PMC191836     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.

Authors:  J E Crowe; C Y Firestone; S S Whitehead; P L Collins; B R Murphy
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

2.  Low-temperature-grown RS virus in adult volunteers.

Authors:  W T Friedewald; B R Forsyth; C B Smith; M A Gharpure; R M Chanock
Journal:  JAMA       Date:  1968-05-20       Impact factor: 56.272

3.  Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.

Authors:  P L Collins; M G Hill; E Camargo; H Grosfeld; R M Chanock; B R Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

4.  Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.

Authors:  C Y Firestone; S S Whitehead; P L Collins; B R Murphy; J E Crowe
Journal:  Virology       Date:  1996-11-15       Impact factor: 3.616

5.  Recombinant vesicular stomatitis viruses from DNA.

Authors:  N D Lawson; E A Stillman; M A Whitt; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

6.  Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones.

Authors:  S P Whelan; L A Ball; J N Barr; G T Wertz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

7.  A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes.

Authors:  M Connors; J E Crowe; C Y Firestone; B R Murphy; P L Collins
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

8.  Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization.

Authors:  J E Crowe; P T Bui; G R Siber; W R Elkins; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1995-06       Impact factor: 3.641

9.  Rescue of measles viruses from cloned DNA.

Authors:  F Radecke; P Spielhofer; H Schneider; K Kaelin; M Huber; C Dötsch; G Christiansen; M A Billeter
Journal:  EMBO J       Date:  1995-12-01       Impact factor: 11.598

10.  A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus.

Authors:  D Garcin; T Pelet; P Calain; L Roux; J Curran; D Kolakofsky
Journal:  EMBO J       Date:  1995-12-15       Impact factor: 11.598

View more
  19 in total

1.  A single amino acid substitution in the phosphoprotein of respiratory syncytial virus confers thermosensitivity in a reconstituted RNA polymerase system.

Authors:  A C Marriott; S D Wilson; J S Randhawa; A J Easton
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination.

Authors:  K Juhasz; B R Murphy; P L Collins
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.

Authors:  Michael N Teng; Peter L Collins
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 4.  Recent vaccine development for human metapneumovirus.

Authors:  J Ren; T Phan; X Bao
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

5.  Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.

Authors:  S S Whitehead; K Juhasz; C Y Firestone; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.

Authors:  M H Skiadopoulos; A P Durbin; J M Tatem; S L Wu; M Paschalis; T Tao; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.

Authors:  T Tao; A P Durbin; S S Whitehead; F Davoodi; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.

Authors:  R A Tripp; D Moore; L Jones; W Sullender; J Winter; L J Anderson
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

9.  Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66.

Authors:  Erich Hoffmann; Kutubuddin Mahmood; Zhongying Chen; Chin-Fen Yang; Joshua Spaete; Harry B Greenberg; M Louise Herlocher; Hong Jin; George Kemble
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.

Authors:  S S Whitehead; C Y Firestone; R A Karron; J E Crowe; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.